The Medical Affairs team at Jounce is hiring! We are seeking a Medical Science Liaison. Jounce has had a strong Medical Science Liaison (MSL) team to support our advancing clinical and research programs since 2019. The MSL position is an exciting opportunity to join a company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and may bring long lasting benefits to patients. The MSLs are highly trained Medical Affairs (MA) professionals with strong clinical and/or scientific backgrounds.
We expect MSLs to have excellent communication and presentation skills. MSLs should demonstrate a solid understanding of immune-oncology as a therapeutic disease area as well as knowledge of clinical trial sites and/or connections with oncology experts. The Medical Science Liaison functions as a field-based, scientific expert who engages health care professionals to exchange clinical, scientific, and research knowledge. By following regulatory and corporate guidelines, they will facilitate and build scientific relationships and collaborations with the medical/scientific community as well as support clinical study initiatives (including patient enrollment in clinical trials). This position interacts with local, regional, and national HCPs; societies; and organizations. Due to the early stage of development of multiple compounds, the MSL will be utilized heavily in supporting clinical operations and clinical development.
In addition to a world-class research organization, Jounce prides itself on a solid translational and reverse translation approach to clinical trials. Currently (though that may change in the future), the focus is mostly on early clinical development (phase 1 and 2). MSLs will need to have a solid understanding of translational approaches within clinical studies while interacting with key clinical experts in the field.
Jounce Therapeutics is an equal opportunity employer and does not discriminate in its employment decisions on the basis of race, color, national origin, age, physical or mental disability, marital status, religion, creed, sex, or political beliefs. We offer a competitive salary and benefits package. All applicants should be legally entitled to work for any employer in the U.S.
To apply, please visit https://careers-jouncetx.icims.com/.
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce’s internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.